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Abstract 
Attention deficit hyperactivity disorder (ADHD) is typically diagnosed using clinical observation and 
subjective informant reports. Once children commence ADHD medication, robust monitoring is required to 
detect partial or non-responses. The extent to which neuropsychological continuous performance tests (CPTs) 
and objective measures of activity can clinically aid the assessment and titration process in ADHD is not fully 
understood. This review describes the current evidence base for the use of CPTs and objectively measured 
activity to support the diagnostic procedure and medication management for children with ADHD. Four 
databases (PsycINFO, Medline, Allied and Complementary Medicine (AMED) and PsycARTICLES) were 
systematically searched to understand the current evidence base for: (1) the use of CPTs to aid clinical 
assessment of ADHD; (2) the use of CPTs to aid medication management; (3) the clinical utility of objective 
measures of activity in ADHD. Sixty relevant articles were identified. The search revealed six commercially 
available CPTs that had been reported on for their clinical use. There were mixed findings with regard to the use 
of CPTs to assess and manage medication, with contrasting evidence on their ability to support clinical decision 
making. There was a strong evidence base for the use of objective measures of activity to aid ADHD/non-
ADHD group differentiation, which appears sensitive to medication effects and would also benefit from further 
research on their clinical utility. The findings suggest that combining CPTs and an objective measure of activity 
may be particularly useful as a clinical tool and worthy of further pursuit.  
 
Keywords: Attention Deficit Hyperactivity Disorder (ADHD); Continuous Performance Tests (CPT), Activity, 
Objective Measures, Systematic Review 
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Introduction 
Attention deficit hyperactivity disorder (ADHD) is a common mental health disorder of childhood 
affecting approximately 4-8% of school age children [1]. This neurodevelopmental disorder is characterised by 
three core symptom domains; inattention, hyperactivity and impulsivity. NICE guidelines provide a blueprint for 
the diagnosis and management of ADHD in England and Wales and indicate the need for young people with 
ADHD to have access to the best evidence-based care in order to fulfil their potential and prevent poor 
outcomes [1]. However, in practice, delivery and quality of care is patchy, with little consistency in assessment, 
diagnosis or management[2]. 
It has been suggested that ADHD is ‘symptom complex’, stemming from multiple causes, such as 
genetics, biological and psychosocial influences [3], resulting in a range of presenting behaviours [4,5]. Given 
the variation in causes and behavioural consequences of ADHD, there is no single test used to diagnose the 
disorder and the clinician’s judgment is currently the most widely accepted method of assessment. For the 
clinician to determine a diagnosis of ADHD they will generally gather information from the parents, teachers 
(and the child themselves where age appropriate), make clinical observations, conduct school observations, and 
may use tests of behaviour and neuropsychological functioning. However, there is a paucity of clinical guidance 
on which combination of measures should be used in the diagnostic assessment of ADHD. Furthermore, this 
approach is heavily reliant on subjective measures, which can lead to discrepancies in the diagnosis of ADHD 
[4] and the process of interview and data collection is lengthy and difficult to conduct in real world settings. 
Additionally, once on medication, monitoring may not be adequate or frequent enough to detect early non- or 
sub-optimal response [6]. Given the subjective nature of ADHD assessment, and the heterogeneous nature of the 
disorder, it is not surprising that it can be seen as a controversial diagnosis amongst clinicians and the public. 
The demonstration of a reliable and valid objective measure to aid this assessment may help partially counteract 
these attitudes.  
Objective measures have the potential to augment and streamline current practice in order to shorten 
assessment time, increase diagnostic accuracy, reduce delays in treatment, and optimise treatment response. 
Continuous performance tests (CPTs) are neuropsychological tests that measure the individual’s attention and 
impulsivity in a sustained task, and can be used alongside clinical inquiry as part of the diagnostic procedure. 
Typically, a CPT is a computer-based programme which involves rapid presentation of visual or auditory 
stimuli. Participants are asked to respond when a given target occurs but to withhold the response to non-targets. 
A standard CPT typically records two of the core features of ADHD; selective attention is measured through the 
child’s omission errors (responding when the target is present), sustained attention is measured through 
decrements in performance during the course of the test, including measures of reaction time and reaction time 
variability, and impulsivity is measured through commission errors (responding when the target is not present). 
The number of correct responses is also recorded.  
Several studies and systematic reviews have demonstrated the ability of CPTs to differentiate children 
with ADHD from other diagnoses or healthy controls [7,8]. Similarly, several papers report CPTs to be sensitive 
to the effects of ADHD medication [8,9]. There are several commercially available CPTs including the Test of 
Variables of Attention (TOVA [10]), the Conner’s CPT (CCPT; Conners [11]), the Gordon’s Diagnostic System 
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(GDS [12]) and the QbTest (QbTech Ltd). Indeed CPTs are considered to be one of the most popular clinic 
based measures to assess sustained attention [13]. However, the majority of CPTs do not measure the patient’s 
activity level, a distinguishing feature of ADHD which may help in accurate differentiation from other 
diagnoses. Current approaches to the objective measurement of activity in ADHD have focused on actigraphy 
devices or infra-red devices to capture movement. Two CPTs, the QbTest and the Quotient ADHD system, 
combine a standard CPT with an infra-red camera which tracks the path of a reflector attached to the 
participant’s head to measure motor activity during the course of the test, allowing information to be gathered 
on all three core symptoms of ADHD.  
Ogundele and colleagues [4] provide a generic overview of the role of CPTs in ADHD and conclude 
that CPTs can provide a more objective insight into the young person’s behaviour and allow parents to gain a 
better insight into the nature of their child’s condition which may also help improve adherence to treatment. 
They suggest that combining CPTs with clinical judgement and rating scales may provide the optimal format for 
diagnosing and managing ADHD. Indeed, there has been an increase in the popularity of the CPTs as a clinical 
tool [11]. However, most research and previous systematic reviews have focused on the psychometric properties 
of the CPT rather than how these tools may aid the clinical assessment or management process of ADHD [14]. 
Given the increase in the use of these tools and that some UK NHS ADHD clinics have incorporated combined 
CPT and objective activity measures as part of standard diagnostic assessment, it is important to understand the 
clinical worth of these tests. 
The aim of this systematic review is to provide an overview of the evidence for commercially available 
CPTs that have been used for aiding the clinical diagnostic and medication process for children and young 
people with ADHD, and in doing so we will identify gaps in the evidence to provide future lines of 
investigation. The review focuses on CPTs that have specifically been investigated for their use as a clinical 
tool, as opposed to neuropsychological test. Given that to date few reviews have focussed on the objective 
measure of activity in ADHD and this variable is increasingly considered an important adjunct to CPTs in 
ADHD assessment [15] we also searched for existing measures which objectively quantify 
activity/hyperactivity. This review was carried out as part of the National Institute for Health Research (NIHR) 
CLAHRC-EM (Collaborations for Leadership in Applied Health Research and Care – East Midlands).  
 
Method 
A systematic search was conducted using the following databases: PsycINFO, Medline, Allied and 
Complementary Medicine (AMED) and PsycARTICLES using the Ovid search engine in June 2014 and 
updated prior to submission in June 2015. Different combinations of various search terms were used to ensure 
that all relevant papers referring to commercially available CPTs for aiding the diagnosis and treatment of 
ADHD or measures of activity movement (such as hyperactivity) were found (see Table 1). Informal searching 
was also undertaken, including hand searching of article references and web search engines (Google). Inclusion 
criteria were: publication in a peer reviewed journal in English; a study of any design focusing on the clinical 
use of CPTs in children or adolescents (aged up to 18 years), or objective measures of activity in children or 
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adolescents. At least some participants in each paper were either diagnosed with ADHD or had been referred for 
an ADHD assessment. Papers were excluded if they did not meet the inclusion criteria, did not include a human 
sample and did not use a commercially available CPT. Titles and abstracts were reviewed by two authors (CLH, 
AZV) according to the inclusion and exclusion criteria; where there was disagreement, this was resolved by 
discussion between the two reviewers. The full text of retained papers was reviewed by these two authors. Data 
extraction was performed by CLH and AZV using a data collection form, any discrepancies were discussed in a 
meeting until consensus was reached.  
<<Insert Table 1 about here>> 
Given that research evidence on the clinical utility of CPTs is likely to incorporate a variety of different 
methodologies, it was considered unwise to include study design as an inclusion criterion. As such, no 
systematic judgments were made about the strengths and weaknesses of each design, however, each method was 
considered in relation to any unique or specific elements of that study in its ability to answer the question posed 
in this review.  
 
Results 
 The combined searches resulted in a total of 1421 articles (after removal of duplicates) of which 60 
articles were identified as relevant and included in the review (Figure 1). 
 
<<Insert Figure 1 about here>> 
 Of the included studies, 24 reported on the clinical utility of CPTs to diagnose (Table 2), 12 reported 
information relevant to the clinical utility of CPTs to aid medication management (Table 3) and 25 reported 
objective measures of activity in ADHD (Tables 4 & 5). Although most studies were based in the USA (30), 
papers were from a variety of locations including: Germany (6), the UK (4), Canada (3), Japan (2), Norway (2), 
Taiwan (3), Australia (1), Denmark (1), Israel (1), Romania (1), South Korea (2), Brazil (1), Spain (1) and 
Sweden (1). In addition, one meta-analysis, conducted in Italy, was included in the review. 
The search identified six commercially available CPTs that had been specifically investigated for their clinical 
utility the: TOVA, GDS, CCPT, Integrated Visual and Auditory Continuous Performance Test ( IVA+CPT), 
Quotient ADHD system (or McLean Motion and Attention Test; MMAT) and the QbTest. Although not the 
purpose of this paper, it is worth mentioning that the included papers from this search cite good psychometric 
properties (e.g., test-retest reliability) of each CPT (e.g., TOVA [16]; GDS [17]; CCPT [18]; IVA+CPT;[19]; 
QbTest [20]; MMAT [21].  
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The clinical use of CPTs to aid the assessment of ADHD 
 The 24 papers that reported on CPTs clinical utility to aid ADHD assessment reported on a combined 
total of five CPTs, of which six papers report on the TOVA [22-25,16,26], 111 report on the GDS [27-32,17,33-
37], five report on the CCPT [38,7,14,39,40], one reports on IVA+CPT [19] and one reports on the QbTest [41]. 
A summary of the papers is presented in Table 2. For the purpose of this review, we considered relevant 
outcomes to include papers that reported: sensitivity/specificity, positive and negative predictive power, 
methods to distinguish group membership or severity of symptoms and feasibility of incorporating the test in 
routine practice. Papers that also qualitatively reported on their experience of using CPTs to aid assessment were 
also included. It should be noted that the above outcomes are likely to differ according to the sample used in the 
study, for example, clinic-referred children are more likely to have a presenting disorder and co-morbidities than 
a community sample. We have highlighted the sample type in Table 2.  
<<Insert Table 2 about here>> 
Test of Variables of Attention (TOVA) 
The TOVA presents a target stimulus in the form of a small square with a hole near the top or bottom 
of the square. Participants are requested to respond by pressing a hand-held switch when the hole is on the top of 
the square and not respond when the hole is on the bottom. The stimuli are presented for 100 milliseconds 
(msec) at a between stimuli interval of 2,000msec; the test lasts for a duration of approximately 22.5 minutes. 
The TOVA utilises both a ‘rare target’ and ‘response inhibition’ paradigm by presenting 22.5% targets and 
77.5% non-targets in the first half of the test and then 77.5% of targets and 22.5% of non-targets in the second 
half of the test. Variables include omission errors (number of missed targets), commission errors (response to 
non-targets), response time (mean response latency), variability (standard deviation of response times), number 
of multiple responses (number of stimuli to which the participant responded more than once) and anticipatory 
responses (very short latency responses). The TOVA also computes an ADHD score using the formula of 
response time Z score (Half 1) +d’Z score (half 2) + variability Z score (total).  The ADHD score is a 
comparison between the participant’s performance to that of a known ADHD sample based on 178 children 
(148 male, 30 female; aged 6-15 years) who had been diagnosed with ADHD by a senior healthcare 
professional. Six studies report information relevant to the clinical utility of the TOVA. Schatz et al.[24] report 
the TOVA’s sensitivity (correct identification of ADHD) and specificity (correct rejection of ADHD) as 85.7% 
and 70.0% respectively in a clinically diagnosed sample of ADHD children and controls. Using the Receiver-
Operating Characteristic (ROC) curve, they found the TOVA was a poorer predictor of ADHD diagnosis than 
the Conners’ Hyperactivity Index, which showed no false positives. Logistic regression showed that only the 
TOVA variable of ‘variability’ was able to significantly predict group membership, with the addition of other 
TOVA variables not improving the ability to predict group membership.  
                                                          
1 Excluding an erratum to the Rielly et al article [27], the correct specificity figures were obtained from the 
Rielly et al erratum [28]. 
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Of the five studies that used the TOVA to specifically aid clinical diagnosis, four reported the TOVA 
to have some clinical utility in aiding the assessment of ADHD [25,26,16,22]. Specifically, the TOVA was 
noted to be easily grasped by children and was useful in aiding the assessment process in children of different 
ethnicities and ages as it avoided the need for linguistic skills and could be easily incorporated into a busy 
outpatient clinic [25]. TOVA was noted by two studies to provide a unique and important source of information 
to the assessment process. Forbes et al. [26] combined TOVA with standard rating scales and found that the 
Revised Conners’ Teacher Rating Scale and TOVA did not identify identical groups of children, with each 
correctly classifying children misclassified by the other measure. They suggest that rating scales and TOVA are 
measuring distinct but important aspects of ADHD and the addition of TOVA makes a valuable contribution to 
assessment of ADHD. In support of this, Chae et al. [16] used TOVA combined with parent and teacher rating 
scales to diagnose ADHD in gifted children. They found the TOVA to be a valid tool in determining ADHD 
diagnosis, and reported that 13.2% of gifted children who were rated as having ADHD on the rating scales, but 
had normal TOVA scores were not classified as having ADHD. The authors suggest that ADHD may be over-
diagnosed if an objective measure such as TOVA is not used in diagnosing ADHD in gifted children, again 
supporting the TOVA alongside rating scales as a unique source of information.  
 Two papers report on the clinical utility of TOVA in determining ADHD sub-types, with mixed results. 
Porumb [22] report a single case study of an 11-year-old girl referred for an ADHD assessment. The author 
reports that although the TOVA did not predict the number of ADHD symptoms, it was useful in determining 
sub-type and in differentiating ADHD from other attention-based symptoms. In contrast, the Forbes et al. [26] 
study reported above, which is based on data from 146 private-practice referred children found  no difference on 
TOVA variables between ADHD and ADD group. 
 Another study [23] found that the TOVA was not clinically useful in distinguishing children with 
ADHD from children with sub-clinical level ADHD-type difficulties. The two groups were sampled using an 
epidemiologically derived sample of children and selecting those at high risk for ADHD. The study compared 
TOVA performance between children meeting the DSM-IV criteria for ADHD and those displaying sub-clinical 
levels of behavioural and cognitive problems. They found no significant difference in TOVA scores between 
these two groups [23], suggesting the TOVA would not be a useful clinical adjunct when determining borderline 
cases. Furthermore, Preston et al. [23] found the TOVA could not predict the number of ADHD symptoms, 
independent of group membership. They concluded that the TOVA does not increase diagnostic accuracy in 
determining ADHD or sub-clinical difficulties in attention/impulsivity/activity, which are the sample likely to 
be seen by a clinician.  
Gordon’s Diagnostic System (GDS) 
 The GDS was designed specifically for clinical use and allows multiple tasks to be administered. The 
GDS provides normative data based upon protocols of 1,300 non-hyperactive boys and girls aged 4-16 years-
old. The GDS consists of three sub-tasks: the Vigilance Task, the Delay Task and the Distractibility Task. The 
Vigilance Task presents numbers on a display screen at the rate of 1/sec. The stimulus is presented for 800msec 
with a 200msec delay. The participant is required to press a button whenever the number 1 is followed by the 
number 9. There are a total of 45 target pairs presented during the task. For young children there is a variant of 
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this task which asks for participants to respond every time a 1 is presented. The Vigilance Task records the 
number of correct responses, number of omissions and commissions. The Delay Task requests the participant to 
not respond. The participant is asked to press a button and wait before re-pressing. If they refrain from re-
pressing for a minimum of 6sec a light flashes and reward points are allocated. If the participant responds prior 
to this the timer resets and no points are awarded. The task records three primary scores: the number of 
responses, the number of correct responses and an Efficiency Ratio (percentage of correct responses). A variant 
of the Vigilance Task was also created to assess the participant’s distractibility. The Distractibility Task is 
identical to the standard Vigilance Task, except for the presence of flashing digits that are presented at random 
intervals on the outer edges of the screen. Administration of all three sub-tasks takes approximately 26 minutes. 
  Twelve papers report on the utility of the GDS to aid clinical assessment of ADHD. One paper 
presents a ROC curve to determine if a child had severe ADHD or was in the community control sample [32]. 
For the three GDS indices of efficiency ratio (generated from Delay Task), commission errors and correct 
response, they found areas under the ROC curve ranging from 0.72-0.73, meaning a randomly selected 
individual with ADHD would have a poorer GDS score than a control child 72-73% of the time. The scores for 
sensitivity varied between the three variables from 49-59% and specificity between 81-87%, suggesting, as a 
single test the GDS was unable to accurate assign group classification.  
 Mayes et al. [33] investigated the GDS accuracy in differentiating subtypes of combined and inattentive 
ADHD. They found the ADHD combined subgroup had greater impulsivity than the inattentive subgroup 
(measured through Delay Task), but were equally impaired on vigilance and distractibility, which measures 
attention, indicating the validity of the Delay Task to aid sub-group differentiation. Classification accuracy of 
the GDS in determining the sub-groups was 69.7% for the Delay Task alone and 70% for Delay plus 
Distractibility. When Combined with WISC Freedom from Distractibility/Working Memory Index and 
Processing Speed Index, the GDS could differentiate ADHD subtypes with 72% accuracy. 
 Trommer et al. [34] found that 28.6% children diagnosed with attention deficit disorder (ADD) 
performed in the normal range on the task, with 35.7% performing within the borderline range and 35.7% 
performing in the abnormal range. Furthermore, 66.6% of non-ADD children performed in the abnormal range 
on the CPT, questioning the sensitivity of this task in aiding group differentiation. However, in order to 
determine the potential effect of IQ on GDS score, Mayes et al [17] scored the GDS relative to IQ to determine 
classification accuracy. Using a 13-point or larger discrepancy between IQ and the GDS to classify ADHD 
combined-type resulted in an accuracy rate of 86% (sensitivity = 90%, specificity = 86%). Of the children who 
had an abnormal GDS score (below 90), 90% had a diagnosis of ADHD (positive predictive power) and 52% of 
healthy control children did not have ADHD (negative predictive power). These figures for positive and 
negative predictive power rose to 91% and 67% respectively when IQ minus the GDS composite was 13 or 
more points. Matier-Sharma et al. [35] report correct classification of 62.5% of ADHD and 94.9% of healthy 
control children on the GDS. Through a series of papers using similar data sets, Grodzinsky and colleagues 
report GDS scores ranging from 83-87% positive predictive power and 59-61% negative predictive power 
[36,37]. 
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 Three studies support the use of the GDS as part of the assessment process [27,28,31,30]. Two papers 
[27,30] found the GDS to be useful for excluding an ADHD diagnosis. Using the IQ GDS cut-point described 
above, Mayes and Calhoun [30] found that 87.8% of children were correctly identified as having ADHD. When 
combining this score with IQ minus Freedom from Distractibility >11, diagnostic accuracy was 90.9%. Their 
findings also showed that the GDS was better at ruling out ADHD than Freedom from Distractibility scores 
(WISC-III) in a clinic referred sample and suggest that GDS should be used in clinical practice with children 
who do not meet ADHD cut-off on Freedom of Distractibility to be confident the child does not have ADHD. 
Rielly et al. [27,28] conducted a classification analysis comparing GDS scores with parent and teacher ratings of 
ADHD in children with language disorder. They found that the GDS showed low positive predictive values 
(20.0% to 36.8%) and high negative predictive values (71.9% to 87.9%), indicating that the test may not be 
useful in diagnosing ADHD. Based on this, Rielly et al. [27] suggest that the GDS is useful as part of a battery 
of assessment to rule out ADHD in communicative disorders clinics, but not in confirming the diagnosis, it 
should be noted that these findings are specific to that found in this specific clinic. The other paper [31] reports a 
series of case studies that used the GDS to aid the assessment process. Gordon concludes that whereas the GDS 
only provides a snapshot on behaviour and should not be used conclusively to form a diagnosis, in each case the 
GDS helped an accurate and efficient assessment, specifically allowing the clinician to use data based on the 
child’s actual behaviour [31].  
 One study reported limited validity of the GDS to aid the assessment process in clinical practice [29]. 
By comparing GDS scores on a clinic sample referred for assessment of ADHD they found that scores on the 
GDS frequently disagreed with the diagnosis of ADHD based on parent interview and behaviour rating scales. 
Based on these results the authors suggested that there is poor ecological validity of the GDS, which may be 
because the test does not correspond to the child’s behaviour exhibited at home, or that rating scales assess 
behaviour over a period of time rather than the snapshot provided by the CPT. Although not suggested by the 
authors, an alternative may be that the GDS is tapping into a unique aspect of ADHD that is not captured by 
rating scales. 
  
Conners’ CPT (CCPT) 
 The CCPT consists of 360 trials in which a single letter appears on the screen for 250ms. The 
participant is asked to press the space bar when every letter appears except X. The CCPT takes approximately 
14 minutes to complete and involves frequent responding. It is based on a ‘response inhibition’ paradigm which 
contains 90% target stimuli and 10% non-target stimuli. In the CCPT the inter-stimulus interval is either 1.5s or 
3s to prevent practice effects. Variables of omission and commission errors, RT, and RT variability are 
calculated. Additionally, the CCPT computes an overall index of attention problems, which is calculated from 
RT, RT variability and omission errors. Norms for the CCPT are based on a non-referred community population 
and clinic-referred cases with an ADHD diagnosis, thus providing T-scores. An overall index that exceeds 11 is 
considered a cut-off for attention problems [14]. Perugini et al. [39] report sensitivity and specificity of 67% and 
73% respectively when classifying ADHD boys from community control boys. Whereas Alloway et al. [38] 
used discriminant function analysis to determine CCPT classification scores for children with ADHD and 
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healthy controls (drawn from a community sample). They report CCPT scores correctly classified 41% of 
ADHD children and 65% of healthy controls, Epstein et al. [7] investigated the prediction of ADHD symptoms 
by CPT performance. They found CPT measures (mean hit RT, hit RT (SE), commission errors, omission 
errors, d’, β) were significantly related to DSM-IV ADHD symptoms but did not demonstrate symptom domain 
specificity [7].  
Kleinman et al. [40] compared patterns of attention deficits on CCPT in children with a diagnosis of bi-
polar disorder (BD), ADHD and combined BD and ADHD with no co-morbidities. They found no significant 
difference in CCPT scores between any groups, suggesting that CCPT scores could not differentiate between 
diagnostic groups. Using cluster analysis based on the CCPT scores, the sample was best clustered into two new 
groups (A+B), which were independent of their original diagnosis. ADHD and BD+ADHD were evenly split 
between the two groups; however, Group A had greater functional impairment on CCPT and rating scales. The 
authors suggest CCPT results may be used to create clinically homogenous groups that could help clinician’s to 
understand the individual’s difficulties and implement specific treatments for these difficulties.  
One study investigated the utility of the CCPT to aid ADHD assessment [14]. Using a clinic-referred 
sample they found no association between CCPT scores and parent and teacher ratings of symptoms, nor could 
the test distinguish between ADHD and clinical controls. They report a further weakness of the CCPT is its 
association with linguistic capability. McGee et al [14] found that phonological skills were associated with 
phonological awareness, and suggest that the task should not be used in children with reading disorders. They 
conclude that the CCPT has questionable value as a diagnostic tool and may be particularly prone to over-
diagnosing ADHD in children with reading difficulties. Although the authors also present the auditory CPT 
(ACPT), they do not discuss this in terms of its use as an assessment tool in clinical practice and it is therefore 
not reported here. 
Integrated Visual and Auditory Continuous Performance Test (IVA+CPT) 
 The IVA+CPT was designed to aid the diagnosis of ADHD and utilises both auditory and visual 
stimuli. Participants are asked to click a button when they hear or see the number ‘1’, but not click when they 
hear or see a number ‘2’. The test takes approximately 20 minutes to complete. IVA+CPT is normed on data 
from 1700 men and women aged 6-96 years. The test computes 12 quotients with separate visual and auditory 
scores. The scores measure omission and commission errors, which are used to calculate a hyperactivity-
impulsiveness and attention deficit scale. Each item consists of 3 auditory quotients and 3 visual quotients. One 
study investigated the clinical utility of quantitative electroencephalography (QEEG) and IVA+CPT to assess 
ADHD [19] . They found all of the IVA+CPT measures were significantly different between the ADHD and 
control group, and report sensitivity of 72.9% and specificity 70.9% in detecting ADHD. The findings suggest 
that the IVA+CPT could be a useful tool in aiding ADHD assessment, however, there is limited research 
investigating this tool for its clinical utility.  
QbTest 
 The QbTest (Qbtech Ltd) combines a CPT to measure attention and impulsivity with an infra-red 
motion capture of head movement to measure activity. The QbTest presents a target stimulus (a grey circle) and 
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a non-target (grey circle with a cross); participants are requested to press a hand-held button every time the 
target is presented. The stimuli are presented on the screen for 100ms, at an interval of 1,900ms. A total of 450 
stimuli are presented with an equal number of targets and non-targets. The stimuli are always presented in the 
same location with a fixed between-stimuli interval. Physical activity is measured during the CPT via an 
infrared camera that tracks the path of a reflector attached to the centre of participant’s forehead. These elements 
of the test provide information on each of the three symptom domains of ADHD and provide summary scores 
for each individual based on deviation from a normative data set, based on age group and gender. The summary 
score for each symptom domain is comprised of 17 parameters, five activity (time active, distance travelled, 
score area, number of micro-events, motion simplicity) and 12 CPT (RT, score outliers, RT variation, 
normalised variation, omission errors, commission errors, normalised commission errors, anticipatory responses, 
multi-responses, D-Prime modified, longest passivity, total error rate). There are two versions of the task for 
children and young people; the task for 6–11-year olds is 15 minutes in duration and the task for 12–17-year 
olds is 20 minutes in duration. The QbTest result is supported by a behavioural observation of events that may 
affect test performance. The QbTest has been approved by the US Food and Drug Administration (FDA) to 
supplement standard clinical assessment and treatment monitoring. To the best of our knowledge the QbTest is 
the only test cleared for both assessment and treatment. 
 One study investigated the clinical utility of the QbTest to aid assessment. Vogt & Shameli [41] 
compared practice outcomes of two groups of children; one group had their assessment without QbTest and one 
group had QbTest added to standard clinical assessment. The outcomes were compared 1-year later and the 
results showed that seven participants (37%) in the non-QbTest had their diagnosis revised (from non-ADHD to 
ADHD) 1-year later, in comparison to none in the QbTest group. Clinician’s decision to initially reject an 
ADHD diagnosis was due to a lack of pervasiveness in the child’s developmental history, or attribution to 
emotional disorder. Of the 19 participants who had a QbTest and did not receive an ADHD diagnosis, scores for 
all three symptom domains (attention, activity, impulsivity) were not outside the normal range. Given the 
clinical difficulty in differentiating ASD and ADHD, it is particularly interesting to note that five participants 
with normal attention and impulse scores that were not diagnosed with ADHD received a diagnosis of ASD. 
The study demonstrates that the QbTest improves diagnostic accuracy and stability, and the addition of the 
activity measure may be particularly useful in distinguishing between disorders with sensory over-responsivity 
(such as ASD).  
 In summary, the papers show mixed findings on the clinical utility of CPTs to aid diagnosis. The 
sensitivity and specificity of the tests to aid group differentiation varies across papers, however, it is important 
to note that the CPT should not be used as a stand-alone tool for diagnosis. Across the CPTs, studies reported 
the utility of including a CPT as an objective measure of symptoms that allow the clinician to directly observe 
behaviour. However, some studies report the CPT cannot accurately differentiate ADHD in clinic referred 
samples. Additionally, several studies report little association between CPTs and rating scales, some studies 
have interpreted this as a lack of validity of the CPT, whereas others suggest the CPT may be tapping into a 
unique factor of ADHD not assessed in rating scales. Further research is required to establish the clinical utility 
of CPTs in aiding the assessment process in clinical practice.  
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The clinical use of CPTs to aid medication management in ADHD 
Twelve papers looked at the clinical utility of CPTs to monitor medication in ADHD, from which five CPTs 
were identified, four papers used TOVA [42-45], three papers used CCPT [46,18,47] two papers used MMAT 
[48,21], two GDS [49,31], and one QbTest [13]. A summary of the papers is presented in Table 3.  
<<Insert Table 3 about here>> 
Test of Variables of Attention (TOVA) 
 The four studies that used the TOVA collectively found mixed reports on its clinical utility to monitor 
medication. Three papers reported that only impulsivity (commission scores) significantly improved on TOVA 
after Methylphendiate (MPH), two papers showed this when looking at the prolonged use of MPH [42], and one 
paper when assessing acute responses [44]. Aggarwal and Lillystone [42] suggest that TOVA as a means to 
assess medication therapy requires more investigation and the test would benefit from a cut-off score that can be 
used to support stopping medication. Huang et al. [44] report that when assessing the acute effects of MPH, the 
second half of TOVA was more sensitive in assessing medication response, which may suggest this half of the 
test should be primarily used to assess medication response. Alternatively, given that the second half of the test 
occurred later than the first half, it may be that in clinical practice conducting the TOVA one and a half hours 
after medication is more effective than one hour or that there is a decrement in sustained attention during the 
course of the test. Wang et al. [45]) showed that during a 24-month period of MPH treatment behavioural 
ratings of ADHD improved, but there was limited correlation between TOVA scores and behavioural ratings. 
Teacher-rated inattention was correlated with TOVA omission errors and the overall ADHD score. Parent-rated 
inattention was correlated with TOVA commission. Measures of psychiatrist rated inattention and hyperactivity 
and impulsivity rated by parent/teacher/psychiatrist did not correlate with TOVA. On the basis of these findings 
the authors recommend getting information from multiple informants to establish medication effects. 
 The fourth paper reports that an objective assessment of medication response is required in children. 
Manor et al. [43] compared children’s subjective reports (Clinical Global Impression of Change) and TOVA 
scores on functioning after taking MPH. They found children (particularly those under 10 years of age) were 
unable to accurately assess their symptoms and improvement, thus conclude including an objective test prior to 
medication initiation and during titration is a valid addition to ADHD monitoring.  
Gordon’s Diagnostic System (GDS) 
 Two papers which reported on the GDS describe mixed findings on the use of the tool to aid 
medication monitoring. Gordon[31] reported the benefit of the GDS in monitoring medication in one case study. 
Tests off medication showed clear difficulties on both the Delay and Vigilance Task, but whilst on medication 
his scores were in the normal or near-normal range. Based on this, the young person was recommended to 
continue stimulant medication therapy and the author concluded that the task was useful in gaining direct 
observations of this child’s behaviour.  
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 In contrast, the findings of Fischer and Newby [49] suggest that the tool is not useful for monitoring 
early medication responses. The authors describe a multi-method protocol implemented in an RCT investigating 
individual children’s responses to medication in clinic. Children sat weekly clinic tests (including the GDS 
Vigilance Task) with the addition of parent and teacher rating scales during titration. They found that GDS 
scores only improved on the highest dose of MPH, however, differences on lower doses were found on other 
tests (see Table 3 for tests), suggesting that the GDS would not be a valuable tool to aid titration.  
Conner’s CPT (CCPT) 
 Three papers support the use of CCPT to aid medication management. Fernández-Jaén et al. [46] aimed 
to assess the efficacy of MPH-extended release (ER). They compared the performance of two groups on a suite 
of attention rating scales and the CCPT. One group sat the tests at baseline (prior to treatment onset) and again 
3-months later, and three hours after taking MPH-ER (group A). For the second group, the tests were conducted 
after achieving optimal MPH-ER dose (three hours after taking it) and repeated approximately one month later, 
with at least a 48 hours suspension in medication before the repeat test (group B). The results showed a 
significant improvement in CCPT scores after MPH-ER. Furthermore, the CCPT was the only test which 
changed significantly in patients in both group A and B. The authors concluded the CCPT was useful in 
determining treatment efficacy, particularly the short-term effects of treatment.  
 Wang et al. [18] used CCPT to monitor effects of MPH, with children sitting the CCPT at baseline, one 
month after baseline (after MPH initiation) and three and six months later. They found during the six month 
period, CCPT scores on impulsivity, hyperactivity and inattention improved, but CCPT assessed distraction did 
not, suggesting this score is not useful for monitoring ADHD in clinical settings.  
Bédard et al. [47] assessed whether ATX and MPH improved performance on CCPT, after patients had 
been titrated to an optimum dose over a period of 4-6 weeks. They found that medication improved measures of 
attention on the CCPT, but not inhibitory control, however, the changes in attention scores for patients on ATX 
were not significant. Scores on the CCPT did not correlate with symptomatic improvement assessed via rating 
scale (ADHD-RS). On the basis of these findings the authors conclude that CCPT does not reflect ADHD 
symptom change, and that using CCPT to titrate mediation may lead to suboptimal outcomes. Together, the 
research reports mixed findings on the clinical utility of the CCPT to aid medication management.  
QbTest 
 Vogt and Williams [13] investigated MPH treatment response after a single dose using the QbTest in 
routine clinical practice. They found the QbTest to be sensitive to the effects of medication, with significant 
effects found for all activity and attention variables. Robust treatment effects were reported in 84% of patients, 
7% showed a partial response and 9% were identified as non-responders based on measures of activity, attention 
and impulsivity. They conclude that adding the QbTest, a CPT that combines activity measurement to routine 
clinical practice, provides important information on behavioural and neuropsychological responses to treatment.   
Quotient ADHD System/ MMAT (formerly known as the McLean Motion and Attention Test (MMAT and 
OPTAx) 
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 The Quotient ADHD system or MMAT takes approximately 15 minutes to complete and combines a 
CPT based on Greenberg’s Minnesota Computer Assessment task [50] with an infrared motion analysis system 
(Qualysus, Gothenberg, Sweden). During the CPT, participants are asked to respond to target shapes by pressing 
a space bar, and inhibit response to non-targets. Unlike the QbTest, the stimuli are presented at random locations 
on the screen. Half the presented stimuli are targets. Stimuli are presented on the screen for 200ms with a 
random interval between stimuli presentation. The CPT measures attention, accuracy (percentage of correct 
responses), omission and commission errors and latency, variability and coefficient variation in responding. The 
infrared motion analysis tracks the location of reflective marker worn on a cap on the participants head. The 
infrared system collects and records movement at 50/sec with a resolution of 0.04mm. A report is produced that 
graphs the participant’s performance on the test. The test is commercially available as the ‘Quotient ADHD 
system’, however, published reports refer to its previous name ‘MMAT’. The test has been cleared by the FDA 
to support ADHD assessment.  
 Two papers report on the use of MMAT in aiding medication management, both report it to be a 
clinically useful tool. Teicher et al. [48] investigated whether MMAT could aid the titration process. Participants 
took part in a four-week triple-blind treatment trial, whereby they received one-week of treatment with placebo, 
and one-week of low, medium and high MPH doses respectively. At the end of each treatment week the MMAT 
was conducted and parents completed the Clinical Global Improvement (CGI) scale at each time point. Results 
showed that in 9/11 (81.8%) cases MMAT identified the dosage parents perceived to be most beneficial, 
suggesting the utility of this tool in monitoring medication. The authors state that MMAT can accurately assess 
a response to 0.4mg/kg dose of MPH and at the time of publishing, they were using this to start the titration 
process in clinic. Tabori-Kraft et al. [21] aimed to evaluate the utility of MMAT in routine medication 
management. Doses were optimised during the first 6-weeks of treatment based on parent and teacher reports 
and clinical observation. After optimisation the child sat the MMAT, before and after stimulant uptake. They 
found that children were less active on stimulant medication and based on CGI scores, 95% of participants were 
reported to be “much” or “very much” improved. The authors conclude that the MMAT should be used in 
medication management to support subjective ratings of improvement. They also note that children were pleased 
with their MMAT report and improvement on and off medication, which may encourage treatment adherence.  
 In summary, the clinical utility of CPTs in aiding medication management in clinical practice is under 
investigated. Most research has been conducted on TOVA which shows limited sensitivity to medication effects, 
with only impulsivity scores improving as a result of medication. However, the QbTest and MMAT which 
combine a measure of activity alongside the domains in other CPTs (attention and impulsivity) have been shown 
to be clinically useful in supporting titration. Combined, the papers demonstrate the need for an objective 
measure of medication response, which may be particularly useful when the CPT combines an activity 
parameter (such as the QbTest and MMAT) to measure all three symptom domains of ADHD.  
Objective measures of activity in ADHD 
 As demonstrated, there has been some evidence investigating the clinical utility of CPTs in aiding 
ADHD assessment and monitoring. However, traditionally CPTs only measure two of the core symptom 
domains of ADHD attention and impulsivity). Our search revealed that more recently two CPTs have been 
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developed that additionally provide an objective measurement of activity (QbTest and MMAT). Yet in 
comparison to objective measures of attention and impulsivity the objective measurement of activity has been 
under-investigated. Therefore we conducted an additional search with the aim of identifying objective methods 
of assessing activity in ADHD. Given the comparative lack of research in objective measures of activity, we did 
not limit our search to papers that used the measures to clinically aid assessment or titration per se, but only 
include papers that discuss the relevance of activity measures to differentiate between ADHD and non-ADHD 
groups or medication effects. Where papers also met our first search criteria, their findings are not repeated 
below. This is the case for four papers [21,51,41,13]. 
 Our search revealed 25 papers and two measures for objectively assessing activity in ADHD: 
accelerometer-based devices (actigraphy and inertial measurement units (IMUs)) and infra-red motion analysis 
(MMAT and QbTest). A summary of the papers is presented in Table 4 and Table 5. An additional paper [52] 
reported a review on actigraphy and motion analysis, this was excluded from our review as not all reported 
papers were on ADHD, however, the relevant articles presented in this review were checked and identified in 
our search. 
Accelerometer-based devices 
 The actigraph was the most commonly cited method of measuring activity. An actigraph measures 
motor activity through an accelerometer. Of the actigraphy studies, ten papers looked at the role of objectively 
measuring activity in diagnosing ADHD or differentiating it from controls [53-62] and six papers objectively 
measured activity and medication [63-68]. Three papers reported using an actigraph which was worn either on 
the participant’s wrist or ankle [53,54,64], ten report using an actigraph worn around the patient’s middle 
[65,67,58,56,59,57,63,60,61,66] and two report use a combination of an actigraph worn on the patient’s leg and 
around their middle [55,62]; one reports a meta-analysis review[68]. 
 Porrino et al.[58] was the earliest paper to show that children with ADHD experienced greater levels of 
activity than children without ADHD during a structured task. One paper used actigraphy to measure children’s 
activity whilst they attended a full-day ADHD clinical diagnostic assessment [54]. They found no difference in 
the activity levels between those who were and were not diagnosed with ADHD in the morning sessions and no 
difference in activity between the ADHD sub-types. However, in the afternoon session, children who were 
diagnosed with ADHD were significantly more active than those without ADHD, suggesting some sensitivity of 
this measure to ADHD, but also highlighting the potential influence on CPT scores depending on the time of 
day. Two papers used actigraphy whilst patients performed laboratory tests  (stop-signal task, choice-task and 
cognitive-experimental tasks) and found recorded levels of activity could differentiate children with ADHD 
from controls [53,55], with Wood et al. [55] reporting ROC area under cure (AUC) values of up to 0.8 for 
actigraphy, differentiating between ADHD, their siblings and controls. Five papers used an actigraph whilst the 
patients sat a non-commercially available CPT [56,57,59-61]. Halperin et al. [56] found that only activity could 
differentiate the ADHD group from non-ADHD psychiatric controls, but could not differentiate ADHD from 
children with anxiety disorders [59]. Rajendran et al. [62] assessed whether scores on NPESY, actigraphy and a 
non-commercial CPT could identify preschool children at risk of ADHD when they were school ages. Typically 
developing and Hyperactive/Inattentive (HI) subgroups (assessed via a rating scale) of 3-4 year olds were 
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assessed for 6 years. Using latent profile analysis, they found that the nature/severity of dysfunction in HI pre-
schoolers did not predict later ADHD diagnosis. All measures could significantly differentiate typically 
developing from HI preschoolers, yet in the HI only preschool actigraphy measures could predict ADHD 
outcome 4 and 5 years later.  
  Hall et al. [60] found children with ADHD were more impulsive (as measured by CPT) and more 
active (measured through an actigraph) during the CPT. Marks et al. [61] found that CPT measured inattention 
correlated with activity. Innoue et al. [57] found that activity measurement could differentiate ADHD from 
healthy controls with sensitivity and specificity of 65% and 76% respectively, additionally combining 
actigraphy with CPT increased the accuracy of ADHD diagnosis than a standard CPT alone. The findings 
suggest the utility of adding an objective measure of activity to a standard CPT to aid assessment.  
 Six papers looked at the role of actigraphy in determining medication effects [65,63,64,67,66]. Porrino 
et al. [67] found a single dose of Dextroamphetamine (Dex) reduced activity by 28%, similarly Donnelly et al. 
[66] also found a reduction in activity after Dex. Borcherding et al. [65] reported that MPH resulted in a greater 
reduction in motor activity than Dex, as measured by actigraphy. De Crescenzo et al.[68] conducted a meta-
analytic review focussing on the role of actigraphy in detecting changes in activity and sleep patterns in RCTs 
investigating the effect of MPH. They conclude that actigraphy was able to assess the effect of MPH on sleep 
and activity, which could be used to support clinical diagnosis and treatment follow-up. Rapoport et al. [63] 
compared activity of hyperactive boys on Dex to a placebo during a gym class. They found that boys receiving 
Dex were less active than boys on the placebo and decrease in activity correlated with teacher reported 
improved behaviour, suggesting that stimulant medication affects activity regardless of the test situation. Konrad 
et al. [64] found a linear effect of MPH dose on actigraphy scores and a relationship between actigraphy scores 
obtained at school and in a neuropsychological test, suggesting that measuring activity in a test situation can be 
a clinically useful way of observing hyperactivity. They also found changes in teacher-rated hyperactive-
impulsive symptoms and inattentive symptoms could be explained by changes in actigraphy scores, highlighting 
the need to include objective measures of activity. Combined, the papers suggest that actigraphy is a valid tool 
to assess medication response.  
O’Mahony et al.[69] investigated the use of IMUs to discriminate ADHD and non-ADHD participants. 
The IMUs were worn on the waist and dominant ankle across five context (in the waiting room with parent, in 
the waiting room with supervisor only, in the consultants room with psychiatrist, in consultants room with 
psychiatrist and parent, and taking the TOVA). Using a support vector machine to classify participants as 
ADHD or non-ADHD, sensitivity of IMU was 94.44% and 95.65%. Specifically, analyses of motion during the 
CPT (TOVA) provided a better performance classification than that achieved during free time. The findings 
support the use of an activity measure during CPT to aid diagnostic assessment.  
Infra-red motion analysis 
 Of the infra-red motion analysis studies, two papers report the use of a specifically designed CPT and 
combined infra-red motion tracker to investigate group differences [51,70]. Teicher et al. [51] used an early 
version of the MMAT system and found children with ADHD moved significantly more than children without-
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ADHD during the CPT, with head movement patterns significantly correlating with teacher ratings of activity, 
this combined CPT and infra-red motion analysis differentiated ADHD children from normal controls with 
88.9% sensitivity and 100% specificity. Reh et al. [70] looked at the factor structure of the QbTest and found 
QbTest scores on activity significantly correlated with teacher ratings of hyperactive behaviours, their analysis 
supported a three-factor model (attention, impulsivity and activity) that was able to explain 76% of variance 
within the sample of ADHD children, with the activity parameter explaining the largest amount of variance. The 
authors conclude the addition of a measurement of activity combined with the CPT constitutes a significant 
advantage for QbTest to aid differentiation of ADHD and non-ADHD cases.  
 Six further studies looked at the effects of medication on combined CPTs and infra-red motion analysis 
[71-76]. Heiser [71]  used MMAT to assess the effect of MPH on ADHD symptoms and found a significant 
improvement on activity parameters after MPH, suggesting MMAT is a useful measure of medication response. 
Wehmeier et al. [74] investigated the efficacy of Atomextine (ATX) on executive functioning. Participants were 
randomised into receiving eight weeks of titrated ATX or placebo. The QbTest was administered at baseline and 
at five points during subsequent weeks (during weeks 1, 2, 4, 6 and 8) and sat in the morning, at noon and late 
noon/early evening. They found that both groups experienced a circadian pattern of outcomes during the day, 
peaking at 10am, declining and then peaking again at 5pm before then declining. ATX was also shown to have a 
positive effect on activity ratings. The sensitivity of the activity measure to ATX was also reported in their 
subsequent paper [72]. Gunther et al. [75] used QbTest to compare long-acting MPH with immediate release, 
and found similar levels of activity between the two groups; the authors conclude that it is important that all 
three symptom domains of ADHD are assessed during titration and medication initiation in order to get the most 
optimal formulation for each individual. Together, these papers support the use of infra-red motion analysis to 
aid differentiation between ADHD and non-ADHD children and to investigate the effect of medication.  
 Ramtvedt and Sundet [73] compared scores on the QbTest with behavioural ratings in children on 
MPH, Dex and a placebo. They found the QbTest scores improved after MPH and Dex but not after placebo, 
with the activity measure having the largest effect size. Additionally, although convergent validity for rating 
scales and the QbTest activity were found on a group level, the measures were not equivalent on an individual 
level for each child. In a paper from the same trial, Ramtvedt et al. [76] used QbTest to investigate the clinical 
gains of including both Dex and MPH in stimulant trials but do not report specifically on activity scores. Their 
findings support the inclusion of the QbTest to monitor medication, which can provide additional information to 
that assessed in rating scales.  
 In summary, objectively assessed activity appears to be sensitive to group differences (ADHD vs. non-
ADHD) and medication effects, suggesting it may be a valuable tool in aiding both the assessment and 
medication management.  
 
Discussion 
 Given the continuing and increasing use of CPTs to aid clinical practice in ADHD, this review sought 
to bring together the current published data on the clinical utility of the CPT in supporting assessment and 
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medication management in children referred or diagnosed with ADHD. This is the first review to focus on the 
clinical application of these tests, and in doing so we can reflect on the current evidence base and identify 
strengths and weaknesses of the CPT as a clinical tool to inform areas for future investigation. A secondary aim 
of this review was to investigate the evidence supporting the objective measure of activity in ADHD. 
 In total, our search revealed six commercially available CPTs that had been investigated for their 
clinical utility (TOVA, GDS, CCPT, MMAT, IVA+CPT and QbTest), of which the TOVA and GDS had the 
largest evidence base for its clinical utility. Together, the evidence indicates mixed findings on the utility of the 
CPT as an assessment tool. Some evidence reported the CPT could not differentiate ADHD from non-ADHD in 
a clinic referred sample [26,23,14], suggesting the tool has limited utility in clinical practice. There were mixed 
findings on the sensitivity and specificity of the CPTs in predicting group membership, however, it is important 
to remember that the CPT should not be used as a stand-alone diagnostic tool, but interpreted within the clinical 
context. Additionally, some studies reported little association between CPT scores and parent/teacher rating 
scales [14,29,16]. However, the interpretation of this result differed between studies. Whereas some questioned 
the validity of the CPT, others suggested it may be tapping into unique aspects of ADHD not assessed in rating 
scales. It is difficult to ascertain which may be the correct interpretation, and further investigation is required to 
compare independently rated clinical diagnosis with clinical diagnosis obtained using CPT scores. One study 
[41] combined a CPT with an objective measure of activity (QbTest) to aid assessment, and found the tool 
improved the clinician’s ability to accurately diagnose ADHD. On the basis of one study it is unwise to draw 
firm conclusions; however, it appears that combining CPTs with objective measures of activity may be 
significantly beneficial.  
 With regard to medication management, the majority of research has focussed on the TOVA, of which 
only scores on impulsivity were shown to improve as a result of medication. A lack of research in this area was 
noted from the review and further research is required to fully understand the utility of CPTs to aid medication 
management. However, CPTs were noted to be useful in providing an objective report in medication response, 
which can be difficult to assess in children who find it hard to accurately report their symptoms and 
improvements [43]. Additionally, CPTs that compute a report documenting symptom changes (such as QbTest 
and MMAT) may increase the child’s motivation and encourage treatment adherence [21]. Again, the papers 
that combined a CPT with motion detection (QbTest and MMAT) were the most clinically useful in 
investigating medication effects, even being sensitive to partial responses and responses on low medication 
doses [13,48] suggesting their utility to aid titration in clinical practice.  
 The secondary search on objective measures of activity in ADHD revealed two methods to currently 
assess activity: accelerometer based devices and infra-red motion analysis combined with a CPT (QbTest and 
MMAT). Both methods were reported to be useful in aiding the differentiation of ADHD/non-ADHD and 
assessing the effects of medication. To date, QbTest is the only CPT that has FDA clearance to aid both the 
assessment and treatment monitoring phase of ADHD in children and young people. Clearly, activity is only one 
of three core symptom domains of ADHD; however, it is currently over-looked in the majority of laboratory 
tests of ADHD. Despite this, the evidence suggests that combining an objective assessment of activity with a 
CPT assessing impulsivity and attention may provide the most clinically useful tool in aiding assessment and 
medication management. It should be noted that no CPT or assessment tool of ADHD is designed to be used as 
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the sole basis for an ADHD diagnosis. However, the addition of such a test to augment clinical practice has 
some supporting evidence base, that is worthy of further investigation, particularly when combined with a 
measure of activity.  
 Our review noted a lack of research investigating the clinical utility of these measures, with most 
research focussing on their psychometric properties. Whilst this is undoubtedly important, for CPTs to be 
validated as a clinical tool, it is necessary to further understand how they aid clinical practice and in which part 
of the assessment or management pathway they may be best placed to optimise patient outcome in a manner that 
is time and cost-effective. We specifically note a lack of randomised controlled trials (RCT) to support the 
clinical use of these measures and the majority of research focuses on group differences, however, in clinical 
practice, the primary concern is diagnostic accuracy for an individual patient. Future RCTs are required to 
ascertain the clinical utility of CPTs in aiding diagnostic accuracy for individual patients referred for an ADHD 
assessment. 
  The quality of this review and its findings are dependent on the quality of the papers assessed. Given 
the lack of trials investigating the clinical utility of the CPT we did not restrict our data to RCT evidence only. 
Additionally, we did not undertake any quality assessment of the papers and their findings. The papers included 
in this review incorporate samples of clinic-referred and community-based samples, which may have influenced 
the clinical utility of the CPT. For example; it could be argued that the ability to differentiate ADHD/non-
ADHD is easier in a community sample than a clinic sample. However, we could not ascertain if this was the 
case given the limited number of community-based samples in the review. In addition, some of the studies used 
specific samples, such as gifted children [16] or children with language disorders [27] which limits the 
generalisability of that papers findings, but is nonetheless relevant to the understanding of the use of the CPT in 
clinical practice. Furthermore, we chose to limit our search to only papers that were available in English and 
thus may have excluded other relevant papers reported in a different language. However, this review is unique in 
its focus on the use of objectively measured attention, impulsivity and activity to aid clinical practice and 
provides an important source for future research, healthcare professionals and service providers.  
 In conclusion, published studies support that CPTs provide an objective method to assess attention and 
impulsivity, but there are mixed reports on whether they are a useful adjunct to clinical practice. The clinical 
utility of these tests to aid assessment and medication requires further investigation, with a particular need for 
RCTs investigating whether the addition of CPTs to standard practice can streamline the ADHD pathway and 
whether they can facilitate speedier, more accurate diagnosis and subsequent cost-savings and improved patient 
outcome. Adding an objective measure of activity allows the CPT to measure all three core symptom domains 
of ADHD and initial evidence suggests this may improve the clinical utility of the CPT.  
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TABLE 1: Search strategies to identify studies for inclusion 
 
Searches: 
1. ADHD OR attention deficit hyperactivity disorder OR attention OR hyper$ OR ADD$ OR attention deficit 
disorder  
2. Continuous Performance Test OR Continuous Performance Task OR Auditory Continuous Performance Test 
OR ACPT OR CANTAB OR Conner$ CPT OR CCPT OR Gordon$ Diagnostic System OR GDS OR Integrated 
Visual and Auditory test OR IVA OR QbTest OR Seidel Continuous Attention Test OR SCAT OR Test of 
Variables of Attention OR TOVA 
3. diagnosing OR assessing OR medication management OR titration OR treatment monitoring OR response 
OR drug OR medication  
4. motor activity OR measure$ OR quantifying 
$ indicates a wildcard character 
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FIGURE 1: Flow diagram illustrating study selection process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Potentially relevant studies identified 
and screened for retrieval 
N = 1421 (after duplicates removed) 
Papers excluded on title and abstract = 1300 
Not: 
i) Humans = 104 
ii) ADHD = 769 
iii) Children (up to 18 years) = 96 
iv) Published in peer review journal = 89 
v) A commercially available CPT = 13 
vi) Clinical utility = 215 
vii) English = 14 
Full papers retrieved from search 
N = 121 
Additional papers identified via hand 
searching 
N = 7 
 
Publications excluded after reading paper = 68 
Not: 
i) Humans = 0 
ii) ADHD = 2 
iii) Children (up to 18 years) = 3 
iv) Published in peer review journal = 3 
v) A commercially available CPT = 1 
vi) Clinical utility = 58 
vii) English = 1 
 
Studies included in review  
N = 60 
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TABLE 2: Continuous performance tasks used for diagnosing ADHD 
Reference  Design CPT test Other assessments Sample Main relevant outcomes 
 
Alloway et 
al. (2009) 
[38] 
Cross-
sectional 
CCPT BRIEF; CTRS-R; 
WMRS 
91 children (66 male, 25 
female):  
46 ADHD; 25 low 
working memory; 20 
control (community 
sample). 
Age: 8-11 years. 
 
CCPT scores did not accurately discriminate between ADHD and 
working memory impairment. CCPT correctly classified 41% of 
children with ADHD, 65% controls and 68% working memory 
impaired children. 
Barkley & 
Grodzinsky 
(1994) [36]  
 
 
Cross-
sectional 
GDS CAP; COWAT; 
Grooved Pegboard 
Test; HMS; PM; Rey; 
Stroop; TMT; WCS; 
WISC-R 
47 children (all male):  
24 ADD/ADHD and 11 
LD (clinic referred); 12 
control (community 
sample). 
Age: 6-11 years. 
 
GDS had reasonably high levels of positive predictive power for 
ADD/ADHD, but was not useful in discriminating between groups.  
GDS had low negative predictive power and high false negative rates. 
Abnormal scores may indicate an ADHD diagnosis, but normal 
scores could not be said to rule out a diagnosis. 
 
Chae et al. 
(2003) [16]  
Cross-
sectional 
 
TOVA  
 
K-CBCL; KEDI-WISC  
SRBCSS; TRFC  
177 children (113 male, 
64 female):  
106 gifted; 71 non-gifted 
(community sample). 
Age: 6-9 years.  
 
13% of gifted children would have been classed as having ADHD 
using the other assessments alone, but were classified as not having 
ADHD as they had normal TOVA scores. Gifted children tend to 
perform better on TOVA. By utilisation of a higher TOVA standard 
9% of gifted children were diagnosed as having ADHD.  
DuPaul et 
al. (1992) 
[29] 
Cross-
sectional 
 
 GDS  ADHD Rating Scale- 
Teacher; CBCL-P/TRF; 
Clinical Interview; 
HSQ – P; MFFT; SSQ 
– Teacher; WISC-R  
68 children (58 male, 10 
female) with ADHD 
(clinic referred). 
Age: 6-11 years. 
Scores on GDS frequently disagreed with the diagnosis of ADHD 
based on parent interview and behaviour rating scales. The 
percentage agreement between classifications rendered by clinic test 
scores and a diagnosis of ADHD based on parent and/or teacher 
report ranged from 12% to 62%.  
 
El Sayed et 
al. (1999) 
[32] 
Cross-
sectional 
 
GDS Clinical interview 
(DSM-IV); WISC; 
other assessments (e.g. 
fine/gross motor 
assessment) 
159 children (126 male, 
33 female): 
71 ADHD (clinic 
referred); 88 control 
(community sample).  
Age: 6-16 years.  
 
GDS was well accepted in both control and clinical groups. 
GDS was able to differentiate between children with ADHD and 
control children. Areas under the ROC curve for GDS performance 
was between 0.72-0.73 for the GDS scores. GDS sensitivity of 49-
59% and specificity of 81-87%. 
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Reference  Design CPT test Other assessments Sample Main relevant outcomes 
 
Epstein et al 
(2003) [7] 
Cross-
sectional 
CCPT Clinical Interviews 
(CAPA); 
816 children (421 male, 
395 female):  
21 ADHD; 795 control 
(community sample). 
Age: 9-17 years.  
 
CCPT measures were significantly related to DSM-IV ADHD 
symptoms but did not demonstrate symptom domain specificity. 
CCPT differentiated children with ADHD from children with no 
diagnosis. 
 
Forbes et al. 
(1998) [26] 
Cross-
sectional 
 
TOVA 
 
ACBC; ACTeRS; B-G; 
CBCL; Clinical 
Interview; CTRS-R 
DCBRS; PPVT-R  
 
146 children (110 male, 
36 female):  
117 ADHD/ADD; 29 no 
ADHD/ADD diagnosis 
(clinic referred). 
Age: 6-12 years.  
 
Teacher rating scales and TOVA did not identify identical groups of 
children, with each correctly classifying children misclassified by the 
other measure. TOVA could not distinguish between ADHD, ADD 
and control children. 
Gordon 
(1986) [31] 
Case study 
series 
 GDS 
 
Clinical Interview/case 
histories 
4 children (3 male, 1 
female) (clinic referred).  
Age: 7-13 years.  
GDS results led to a diagnosis of ADHD in children who showed 
ADHD symptoms during initial observations, as well as in those who 
did not show symptoms. Consistencies and inconsistencies in 
behavioural responses led to further assessments being performed. 
GDS helped clinical assessment.  
 
Grodzinsky 
et al., 
(1999) [37]  
 
Cross-
sectional 
GDS COWAT; HMS; PM; 
Rey; Stroop; TMT; 
WCS  
130 children (all male):  
66 ADHD (clinic referred 
and/or diagnosed); 64 
control (community 
sample). 
Age: 6-11 years.  
 
Significantly more participants with ADHD had abnormal GDS 
scores than the control group. Positive predictive power based on 
correct responses was 87% and based on commission errors was 
83%. Negative predictive power (NPP) based on correct responses 
was 61% and based on commission errors was 59%. 
 
Kim et al 
(2015) [19] 
Cross-
sectional 
IVA+CPT QEEG; Korean DISC-
IV 
157 children (118 males, 
39 females) 
85 ADHD; 72 control 
(sample attending 
attention support group). 
Age: 9 years (mean). 
 
IVA+CPT measures were significantly different between the ADHD 
and control group. IVA+CPT sensitivity of 72.9% and specificity 
70.9% in detecting ADHD.  
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Reference  Design CPT test Other assessments Sample Main relevant outcomes 
 
Kleinman et 
al. (2015) 
[41] 
Cross-
sectional 
 
CCPT K-SADS-PL; K-SADS-
E; CGAS; Wechsler 
Abbreviated Scale of 
Intelligence; CDRS-R; 
YMRS; SNAP-IV 
 
84 children (54 male, 30 
female): 
23 ADHD; 10 Bipolar 
(BD); 33 BD+ADHD (all 
clinic referred); 18 control 
(community sample).  
Age: 12-17 years. 
 
No significant difference in CCPT scores between any groups, The 
sample was best clustered into two new groups (A+B), which were 
independent of their original diagnosis. ADHD and BD+ADHD were 
evenly split between the two groups. 
 
Matier-
Sharma et 
al. (1995) 
[35]  
 
Cross-
sectional 
GDS Actigraph 129 children (100 male, 
29 female):  
40 ADHD; 57 non-
ADHD; 14 excluded 
subthreshold ADHD 
(clinic referred); 18 
control (community 
sample). 
Age: 6-13 years.  
 
Children with ADHD made significantly more errors and were more 
active than the other groups. GDS correctly classified 63% of ADHD 
and 94% of control children. Poor performance on GDS generally 
indicated ADHD but normal performance could not rule out ADHD. 
Specificity was between 0.83-0.94 for ADHD vs control children.  
Mayes & 
Calhoun 
(2002) [30]  
Cross-
sectional 
 
 GDS 
 
WISC-III 230 children (180 male, 
50 female):  
184 ADHD; 46 without 
ADHD (clinic referred). 
Age: 6-16 years.  
 
IQ minus GDS composite score > 13 correctly identified 88% of 
children as having ADHD, this increased to 91% when combined 
with Freedom from Distractibility >11. GDS was useful for 
excluding an ADHD diagnosis. GDS was better at ruling out ADHD 
(70%) than WISC-III (31%). 
Mayes et al. 
(2001) [17] 
Cross-
sectional 
GDS Clinical interview 
(DSM-IV) & 
observation; PBS; 
WISC-III; WIAT 
211 children 
(approximately 163 male):  
165 ADHD; 46 without 
ADHD (clinic referred). 
Age: 6-16 years.  
 
GDS sensitivity was 90% and specificity 70%. 90% of children with 
an abnormal GDS score had a diagnosis of ADHD and 52% of 
children with a normal GDS score did not have ADHD.  
When IQ minus GDS score IQ >13, this increased positive predictive 
power to 91% and negative predictive power 67%.   
Mayes et al. 
(2009) [33] 
Retrospective 
analysis of 
clinical data 
GDS Clinical interview 
(DSM-IV); WISC-
III/WISC-IV; 
WIAT/WIAT-II; PBS 
587 children (gender not 
specified) with ADHD 
with or without a co-
morbid disorder (clinic 
referred). 
Age: 6-16 years.  
 
Classification accuracy for combined and inattentive ADHD was 
70% for both Delay and for Delay + Distractibility errors, falling to 
46% accuracy in predicting diagnosis for ADHD subgroups. Overall, 
GDS differentiated between ADHD subgroups with 72% accuracy.  
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Reference  Design CPT test Other assessments Sample Main relevant outcomes 
 
McGee et 
al. (2000) 
[14] 
Cross-
sectional 
 
CCPT  CBCL; Clinical 
Interviews (DSM-IV); 
CPRS; CTRS; GORT; 
WIAT; WISC 
100 children (79 male, 21 
female):  
40 ADHD; 14 RD; 14 
ADHD + RD; 32 control 
(clinic referred).  
Age: 6-11 years. 
  
The CCPT did not distinguish between ADHD and clinical controls. 
Children with ADHD did not have higher scores than clinical 
controls; children with RD did. The CCPT task should not be used in 
children with reading disorders. 
 
 
Perugini et 
al. (2000) 
[39] 
Cross-
sectional 
CCPT COWAT; K-ABC;  
Stroop test; Trail 
Making Test; WISC-III  
43 children (all male):  
21 diagnosed with ADHD; 
22 control (community 
sample). 
Age: 6-12 years.  
 
CCPT sensitivity of 67% and specificity of 73%. CCPT was more 
accurate in predicting ADHD than other measures alone, but the 
predictive validity increased further when measures were considered 
in combination. 
  
Porumb 
(2007) [22] 
Case study TOVA NEPSY 1 child (female) with  
ADHD (clinic referred). 
Age: 11 years.  
 
TOVA did not predict the number of ADHD symptoms, but did assist 
in diagnosis, particularly in discriminating from other disorders. 
TOVA could identify the ADHD subtype. 
Preston et 
al. (2005) 
[23] 
Cross-
sectional 
 
TOVA Clinical interview 
(DISC-IV); SNAP IV-P 
SNAP IV-T 
167 children (67 male, 
100 female):  
116 ADHD; 51 sub-
clinical ADHD control 
(community sample). 
Age: 6-14 years.  
 
No significant difference in TOVA performance of children with 
ADHD than those with sub-clinical levels. TOVA did not predict 
number of ADHD symptoms independent of group membership. 
TOVA did not increase diagnostic accuracy in determining ADHD or 
sub-clinical difficulties in attention/impulsivity/activity. 
 
Rielly et al. 
(1999) [27] 
Cross-
sectional 
 
 GDS 
 
DBDRS-P; DBDRS-T 
WISC-R 
 
99 children (all males) 
with language disorder 
(clinic referred) 
Age: 7-9 years.  
 
Comparisons with rating scales showed low positive predictive 
values (20%-37%) but high negative predictive values (72%-88%). 
GDS accurately disconfirmed ADHD; likelihood ratios for normal 
scores were low to moderate (0.41 to 1.16).  
Schatz et al. 
(2001) [24] 
Cross-
sectional 
TOVA CPRS 
 
48 children (gender not 
specified):  
28 diagnosed with ADHD; 
20 control (community 
sample). 
Age: 5-17 years.  
 
TOVA sensitivity of 86% and specificity of 70%. TOVA variability 
and RT differentiated between ADHD and non-ADHD groups. 
Variability predicted group membership. 
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Reference  Design CPT test Other assessments Sample Main relevant outcomes 
 
Trommer et 
al. (1988) 
[34] 
Cross-
sectional 
GDS REITAN tests; WISC-R 20 children (14 male, 6 
female):  
14 ADD; 6 non-ADD 
(clinic referred). 
Age: 5-14 years.  
 
The sensitivity of GDS was questioned. Using GDS, 29% of children 
diagnosed with ADD performed in the normal range, 36% in the 
borderline range and 36% in the abnormal range. 67% of non-ADD 
children performed in the abnormal range. 
Vogt & 
Shameli 
(2011) [41] 
Pre-test post 
test 
 
QbTest 
 
Clinical Interview; 
CPRS-R (long & short) 
CTRS-A; SDQ 
108 children (gender: not 
reported):  
70 ADHD; 38 not ADHD 
(clinic referred). 
Age: 9/10.5 years (mean).  
 
QbTest reduced the risk of unidentified ADHD. 7 participants who 
had not received a QbTest had their diagnosis revised (from non-
ADHD to ADHD) 1-year later. 5 participants with normal attention 
and impulse scores were diagnosed with ASD. QbTest improves 
diagnostic accuracy and stability.  
Wada et al. 
(2000) [25] 
Cross-
sectional  
TOVA 
 
Clinical Interview; 
CPRS; CTRS; WISC-R 
36 children (all male) 
17 ADHD; 19 control 
Age: 6-12 years  
 
 
TOVA was easily understood by both children and parents and was 
easy to administer in children with varying ethnicities and ages. 
Children with ADHD had higher means on all TOVA variables than 
those without ADHD.  
ACBC Achenbach Child Behaviour Checklist, ACTeRS ADD-H Comprehensive Teacher’s Rating Scale, B-G Bender-Gestalt, BRIEF Behavior rating inventory of executive 
function, CAPA Child and Adolescent Psychiatric Assessment, CBCL(-P) Child Behaviour Checklist (-Parent), CBCL-TRF Child Behaviour Checklist-Teacher Report Form, 
CDRS-R Children;s Depression Rating Scale-Revised, CGAS Children’s Global Assessment Scale, COWAT The Controlled Oral Word Association Test or F-A-S, 
CPRS/CTRS(-R)(-A) Conners’ Parent/Teacher Rating scale (-Revised) (-Abbreviated), DBDRS-P/DBDRS-T Disruptive Behaviour Disorders Rating Scale – Parent/Teacher, 
DCBRS Devereux Child Behaviour Rating Scale, DISC-IV The Diagnostic Interview Schedule for Children, GORT Gray Oral Reading Test, HMS Hand Movements Scale, 
HSQ(-P) Home Situations Questionnaire (-Parent), K-ABC Kaufman Hand Movements Scale from the K-ABC, K-CBCL Korea Children Behaviour Checklist, KEDI-WISC 
Korean Educational Development Institute-Welscher Intelligence, K-SADS-PL/-E Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and 
Lifetime version/-Epidemiological version,  MFFT Matching Familiar Figures Test, NEPSY A Developmental NEuroPSYchological Assessment, PBS Pediatric Behavior 
Scale, PM Porteus Mazes, PPVT-R Peabody Picture Vocabulary Test-Revised, RD Reading disorder, REITAN TESTS The Category and Tactile Performance Tests from the 
Halstead-Reitan Neuropsychological Test Battery for Older Children or Reitan-Indiana Neuropsychological Test Battery for Young Children, Rey Rey-Osterrieth Complex 
Figure, SDQ Strengths and Difficulties Questionnaire, SNAP-IV-P/T Swanson, Nolan & Pelham-IV (Parent/Teacher), SRBCSS Scale for Rating the Behavioural 
Characteristics of Superior Students, SSQ-T School Situations Questionnaire (-Teacher), Stroop Stroop Color-Word Test, TMT Trail Making Test, TRFC Teacher Report 
Form, WIAT Wechsler Individual Achievement Test, WISC-R/-III/-IV Wechsler Intelligence Scale for Children-Revised/-III/-IV, WCS Wisconsin Card Sorting Test, WMRS 
Working Memory Rating Scale, YMRS Young Mania Rating Scale  
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TABLE 3: Continuous performance tasks used for medication management in ADHD 
Reference  Design CPT test Other assessments Sample Medication Main relevant outcomes 
 
Aggarwal 
and 
Lillystone 
(2000) [42] 
 Pre-post test  
 
TOVA CBCL; Clinical 
interviews (DSM IV); 
CPRS 28; CTRS 28 
 
 
18 children (16 male, 2 
female) with ADHD. 
Age: 8-16 years.  
 
Dex or MPH Significant improvement in mean commission 
errors after prolonged use of medications. Omission 
errors, response time and variability did not 
significantly improve after medications. Significant 
positive correlation between commission and 
omission scores. 
 
Bédard et al. 
(2015) [47]  
 
Double-blind 
crossover RCT 
 
CCPT K-SADS-PL; clinician 
judgement  
 
 
 
101 children (77 male, 24 
females) with ADHD. 
Age: 6-17 years. 
MPH + ATX Medication improved measures of attention on the 
CCPT, but not inhibitory control, however, the 
changes in attention scores for patients on ATX 
were not significant. Scores on the CCPT did not 
correlate with symptomatic improvement assessed 
via rating scale (ADHD-RS). 
 
Fernández-
Jaén et al. 
(2009) [46] 
Pre-post-test  CCPT ADHD-RS; D2 Test; 
EMA 
 
94 children (69 male, 25 
female) with ADHD. 
Age: 6-18 years.  
 
MPH-ER 
 
84% showed lower ADHD-RS score on MPH-ER. 
77% improved omission and 55% commission after 
MPH-ER. CCPT was the most effective test for 
monitoring short-term effects of MPH. 
 
Fischer & 
Newby 
(1991) [49] 
Double blind 
randomised 
placebo 
controlled trial  
GDS-
Vigilance 
Task  
CBCL; CPRS-R; 
CTRS-R; HSQ; 
Side effects rating 
scale; SSQ 
161 children (141 male, 20 
female) with ADHD. 
Age: 2-17 years.  
 
MPH GDS scores improved on both low and high doses 
of MPH compared to placebo. However, only the 
higher doses of MPH resulted in significant 
improvements on GDS scores. 
 
Gordon 
(1986) [31] 
Case study 
series 
GDS Clinical interview/case 
histories 
4 children (3 male, 1 
female) with ADHD 
Age: 7-13 years  
 
 
Stimulant 
Medication 
Delay and Vigilance Task scores were in the 
normal or near-normal range on medication but 
were impaired without medication. GDS led to 
recommendations to continue stimulant 
medications. 
 
Huang et al. 
(2007) [44] 
Pre-post test 
 
TOVA Clinical Interviews 
(DSM-IV &  
K-SADS-E); WISC-III 
57 children (50 male, 7 
female) with ADHD 
Age: 6-13 years  
 
MPH  One dose of MPH enhanced commission errors, 
response time and ADHD scores, but not omission 
errors, response time variability or d′. Second half 
of TOVA was more sensitive in determining MPH 
effects. 
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Reference  Design CPT test Other assessments Sample Medication Main relevant outcomes 
 
Manor et al. 
(2008) [43] 
Pre-post test 
 
TOVA CGI-C; Clinical 
Interview; CPRS; 
CTRS; SDQ-P; SDQ-T 
165 children (110 male, 55 
female) with ADHD 
Age: 5-18 years  
 
  
MPH All TOVA indices improved after MPH. Largest 
improvement in the commission mean score and the 
least improvement in the omission mean score. The 
older the patient the more prone he/she was to 
perceive improvement. 
 
Tabori-
Kraft et al. 
(2007) [21] 
Pre-post-test 
 
MMAT CGI; Clinical 
Interview;  
DuPaul Questionnaire; 
WISC-III 
 
23 children (22 male, 1 
female) with HKD or 
ADD Age: 7-12 years  
 
Dex 
MPH 
Children showed a significant improvement on 
MMAT when on medication compared with no 
treatment. The improvement measured by MMAT 
was supported by clinical assessment. Children 
were pleased with their OPTAx report 
 
Teicher et 
al. (2008) 
[48] 
Triple-blind 
within-subject 
efficacy study 
MMAT CGI; Clinical Interview 
(DSM-IV, K-SADS-E 
5th) 
 
11 children (all males) 
with ADHD. Age: 6-12 
years  
 
MPH MMAT identified the dosage parents perceived to 
be most beneficial in 82% of cases. MMAT can 
accurately assess a response to 0.4mg/kg dose of 
MPH.  
 
Vogt and 
Williams 
(2011) [13] 
Pre-post-test  QbTest CPRS- R (short & 
long); CTRS-A; SDQ-
P  
44 children (36 male, 8 
female) with HKD 
Age: 7-18 years  
MPH 84% had improvements on MPH with measures 
(activity, attention, impulse control) reverting to the 
“normal” population mean. 7% demonstrated a 
partial response to MPH. 9% were non-responders. 
 
Wang et al. 
(2011)[18] 
Pre-post-test CCPT  
 
ADHD-RS; CBCL; 
SNAP-IV 
50 children (40 male, 10 
female) with ADHD 
Age: 6-12 years  
MPH Over 6 months of MPH treatment, CCPT scores on 
impulsivity, hyperactivity and inattention improved, 
but CCPT assessed distraction did not. 
 
Wang et al. 
(2015) [45]  
 
Longitudinal TOVA 
 
SNAP-IV; ADHD-RS 
 
181 children (151 male, 30 
female) with ADHD 
Age: 8-18 years 
MPH  
 
Limited correlation between TOVA scores and 
behavioural ratings.  
 
 
ADHD-RS Attention-Deficit/Hyperactivity Disorder Rating Scale, ATX atomexetine, CBCL Child Behaviour Checklist, CGI(-C) Clinical Global Impression (-change scale), 
CPRS/CTRS (-A)(R)(28) Connors’ Parent/Teacher Rating Scale(-Abbreviated) (-Revised) (-28 item), Dex Dexamphetamine, HSQ Home Situations Questionnaire, K-SADS-
PL/-E Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version/-Epidemiological version, MPH Methylphenidate, MPH-
ER Methylphenidate Extended Release, SDQ-P/T Strengths and Difficulties Questionnaire- Parent/Teacher, SNAP-IV Swanson, Nolan & Pelham-IV, SSQ School Situations 
Questionnaire, WISC-III Wechsler Intelligence Scale for Children-III, D2 Test Brickenkamp’s D2 Test, EMA Escalas Magallanes de Attencion Visual Face Perception Test
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TABLE 4: Objective measures of activity in ADHD using actigraphy 
Reference Design Activity test Other assessments Sample  Main relevant outcomes 
Alderson et 
al. (2012) [53] 
Cross-sectional 
 
MicroMini 
Motionlogger (R) 
Actigraph 
(Ambulatory 
Monitoring, 2004) 
CBCL; Clinical 
Interview (DSM-IV, K-
SADS); CSI- P; CSI- T 
TRF; WISC-III/IV 
22 children (all males):  
11 with ADHD 
(clinic/community 
referred); 11 control 
(community sample).  
Age: 8-12 years.  
 
Children with ADHD were more active than typically 
developing children across all experimental conditions. 
All children exhibited significantly higher activity rates 
under all experimental tasks relative to control.  
 
Borcherding 
et al. (1989) 
[65] 
Double blind 
crossover trial 
Actigraphy n/a 18 children with ADHD 
(all male) (community and 
clinic sample). Age: 9.6 
years (mean). 
 
MPH resulted in a greater reduction in motor activity as 
measured by actigraphy than Dex.  
Dane et al. 
(2000) [54] 
Repeated 
measures 
Actigraph 
(Ambulatory 
Monitoring Inc, 
1996) 
 
Clinical Interview 
(DSM-IV); IOWA-C-
10; OCHS; PICS; TTI 
64 children (49 male, 15 
female):  
42 with ADHD; 22 control 
(clinic referred). Age: 7-12 
years.  
 
No significant differences in activity between children 
with ADHD and controls in the morning session. 
Children with ADHD were significantly more active 
than controls during the afternoon session, but there were 
no differences between ADHD subtypes. 
DeCrescenzo 
et al. 
(2014)[68] 
Meta-analysis of 
placebo 
controlled 
crossover trials 
(MPH/Placebo) 
 
Actigraphy n/a 8 papers 
393 children (187 male, 
206 female) with ADHD. 
Age: 6-12 years. 
 
Actigraphy was able to assess the effect of MPH on sleep 
and activity. Actigraphy showed MPH can negatively 
affect total sleep and reduce mean activity in ADHD 
children compared to a placebo. 
Donnelly et 
al. (1989)[66] 
Double blind 
crossover 
placebo 
controlled trial 
Actigrapy CBRS; CGAS; CPQ; 
CPRS 
20 ADHD children (male) 
(community & clinic)  
Age: 6-12 years. 
 
Immediate marked improvement in disruptive, 
overactive behaviour after Dex. No effect with FEN. 
 
Hall et al. 
(1997) [60] 
Cross-sectional Actigraphy CBCL; CBQ; CTQ; 
PPVT-R; RCPM; 
WRAT-R 
70 children (47 male, 23 
female) (clinic referred). 
Age: 6-13 years. 
Children with ADHD were more impulsive regardless of 
whether there was reading disability present. ADHD 
children more active than non-ADHD. 
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Reference Design Activity test Other assessments Sample  Main relevant outcomes 
Halperin et al. 
(1992) [56] 
Cross-sectional  
 
Solid state 
Actigraphs 
 
Halperin CPT 
CBCL; Clinical 
Interview (DSM-III-R); 
CTRS; PIAT-R; 
PPVT-R; RCPM; 
WRAT-R 
102 children (83 male, 19 
female):  
31 with ADHD and 53 
without ADHD (clinic 
referred); 18 control 
(community sample).  
Age: 6-13 years.  
 
Patient groups were inattentive in comparison to control 
children but differences were not significant. The ADHD 
group was more active than both non-ADHD patients 
and control children; who did not differ from one 
another. 
Halperin et al. 
(1993) [59] 
Cross-sectional  Solid state 
actigraph 
(Ambulatory 
Monitoring Inc) 
Halperin CPT;  
RCPM or WISC-R 66 children (52 males, 14 
females):  
13 ADHD; 20 anxiety 
disorder; 15 disruptive 
disorders (ODD/CD) 
(clinic referred); 18 control 
(community sample).  
Age: 6-13 years. 
  
Activity measures were able to distinguish the ADHD 
children from the control children, but did not 
distinguish between patient groups.  
Inoue et al. 
(1998) [57] 
Cross-sectional  
 
Solid-state 
actigraph  
CPT 
MFFT; WISC-R-JV 72 children (all males):  
20 with ADHD (clinic 
referred); 52 control 
(community sample). 
Age: 6-12 years.  
 
Actigraph activity measured during the 10 minutes of 
CPT, and the commission and omission errors of the 
CPT differentiated the ADHD group from the control 
group with sensitivity of 65% and specificity of 76%. 
Konrad et al. 
(2005) [64] 
Double-blind 
Placebo-
controlled 
(MPH/Placebo) 
 
Actigraphy 
(Cambridge 
Neurotechnology, 
version 2.56, 
Cambridge, UK) 
CBCL; Clinical 
Interview (DSM IV);  
FBB-HKS; K-DIPS; 
WISC III IQ 
44 children (37 male, 7 
female) with ADHD 
(clinic referred).Age: 8-12 
years. 
 
 
MPH produced significant improvements in both 
objective and subjective measures of ADHD. There was 
a linear effect of MPH dose on activity and a relationship 
between actigraphy scores at school and in test situation. 
Marks et al. 
(1999)[61] 
Cross-sectional Actigraphy  CAS-T & P; CBCL; 
CPT; IOWA-CTQ;  
WISC 
66 children (all males) 
with ADHD (clinic 
referred). Age: 7-11 years. 
  
CPT measured inattention correlated with activity. 
Lab based measures enabled clinicians to distinguish 
between four groups of ADHD (hyperactive-inattentive, 
impulsive-inattentive, inattentive only, hyperactive only) 
and may provide a useful tool in assessment/diagnosis. 
 
O’Mahony et 
al (2014) [69]  
 
 
Cross-sectional Intertial 
measurement units  
ADHD-rating scale; 
TOVA; clinical 
judgment 
43 clinic-referred children: 
24 ADHD (17 male), 19 
non ADHD ( male). Age: 
6-11 years 
Sensitivity of IMU was 94.44% and 95.65% in 
classifying ADHD or non-ADHD.  
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Reference Design Activity test Other assessments Sample  Main relevant outcomes 
Porrino et al. 
(1983a) [58] 
Cross-sectional Actigraphy (solid 
state) 
Activity diary (hourly); 
CPT; CPRS; CTRS-A. 
24 children (all males):  
12 hyperactive; 12 control 
(community and clinic 
sample). Age: 6-12 years. 
 
Hyperactive children had higher activity levels than 
matched controls across both day and night. Differences 
in activity were greater during structured school tasks. 
 
Porrino et al. 
(1983b) [67] 
Double blind 
ABAB design 
(Dex/Placebo)  
Actigraphy  CTRS; CPRS; TRS 12 hyperactive children 
(all male) (community and 
clinic sample). Age: 6-12 
years. 
 
A single dose of Dex reduced activity for 8 hours after 
administration with a rebound effect occurring in the 
early evening and during sleep. CPT changes were 
minimal due to timing of test. 
Rajendran et 
al. (2015) [62]  
 
 
 
 
Longitudinal 
 
 
 
 
 
Actigraphy 
 
 
 
 
 
NEPSY; Kiddie CPT; 
K-SADS: present & 
lifetime; Nakao-Treas 
Socioeconomic 
prestige index  
 
214 children (156 male, 58 
female): 
105 hyperactive/ 
inattentive, 51 control 
(community sample). 
Age: 3-4 years at baseline 
Actigraphy could significantly differentiate typically 
developing from hyperactive/inattentive pre-schoolers. 
Only actigraphy could predict ADHD outcome 4 and 5 
years later. 
 
 
Rapoport et 
al. (1980) [63] 
Double-blind, 
Placebo-
controlled 
 
Actigraphy Behaviour ratings; 
CTRS; Skill ratings; 
WISC 
10 children (all males) 
with hyperactivity/ 
impulsivity (clinic 
referred). Age: 9 years (m) 
 
Dex use produced lower activity levels relative to 
placebo. The decrease in activity correlated with teacher 
reported improved behaviour. 
Wood et al. 
(2009) [55] 
 
 
 
 
 
Cross-sectional 
 
 
 
 
 
 
2 Actigraphs: 
1) MTI Health 
Services, V323 
2) Health One 
Technology, 
Pensacola, FL 
 
Clinical Interview 
(DSM-IV); CPRS-LV 
CTRS-LV; PACS 
 
 
 
 
507 children (approx 332 
males): 116 with ADHD & 
119 siblings (International 
Multicentre ADHD 
Genetics project); 250 
control (community 
sample). Age: 6-18 years.  
 
High ADHD actigraph familial correlations in activity. 
Actigraph measures yielded an area under the curve of 
up to 0.8, indicating an ability to distinguish between 
cases and controls. 
 
 
 
CAS-T/P Children’s Aggression Scale-Teacher/Parent, CBCL Child Behavior Checklist, CBQ Child Behaviour Questionnaire, CBRT Conners brief rating scale (Teacher) 
CGAS Clinical Global Impression Scale, CSI-P/T Child Symptom Inventory – Parent/Teacher, CTQ/CPQ Conners Teacher’s/Parent’s Questionnaire, CTRS/CPRS (-LV/A) 
Conners’ Teacher Rating Scale / Conners’ Parent Rating Scale (-Long Version/-Abbreviated), FEN Fenfluramine hydrocholoride, IOWA-C-10 IOWA-Conners rating scale 
(10 item), IOWA-CTQ IOWA-Conners Teacher’s Questionnaire, KITAP Test of Attentional Performance for Children, K-SADS(-E) Kiddie-Schedule for Affective Disorders 
and Schizophrenia for School-Aged Children (Epidemiologic Version), MFFT Matching Familiar Figures Test, NEPSY Developmental Neuropsychological Assessment, 
OCHS Ontario Child Health Study Scales, PACS Parental Account of Childhood Symptoms, PIAT-R Peabody Individual Achievement Test Revised, PICS Parent Interview 
for Child Symptoms-IV, PPVT-R Peabody Picture Vocabulary Test-Revised, RCPM Raven’s Coloured Progressive Matrices, TRF Teacher Report Form, TTI Teacher 
Telephone Interview-IV, WISC-(III/IV/JV/R) Wechsler Intelligence Scale for Children-(III/IV/Japanese version/Revised), WRAT-R Wide Range Achievement Test Revised 
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TABLE 5: Objective measures of activity in ADHD using infra-red motion analysis 
Reference Design Activity test Other assessments Sample Main relevant outcomes 
 
Gunther et al. 
(2012) [75] 
Pre-post-test 
RCT (MPH-
ret/MPH-IR)  
QbTest CBCL; Clinical 
Interview (DSM-IV-
TR); FBB-HKS (T) 
K-DIPS; WISC-III 
56 children (43 male, 13 
female):  
36 with ADHD (clinic 
referred); 20 control 
(community sample). 
Age: 8-12 years. 
 
Significant differences were identified between groups in 
inattention, hyperactivity and impulsivity. Both MPH-ret 
and MPH-IR groups improved after medication, and 
behaviour was comparable to control children. MPH-IR 
was better than MPH-ret in reducing impulsivity. 
 
Heiser et al. 
(2004) [71] 
Pre-post-test 
(MPH) 
 
MMAT (OPTAx) CBCL; Clinical 
Interview (ICD-10) 
25 children (20 male, 5 
female) with hyperkinetic 
disorders (clinic referred). 
Age: 6-12 years. 
 
Significant improvement in activity, impulsivity, and 
attentiveness after MPH. 
 
Ramtvedt & 
Sundet 
(2014)[73] 
Secondary 
analysis of 
Ramtvedt et al. 
(2013) 
(MPH/Dex/ 
Placebo) 
 
QbTest ADHD-questionnaire 36 children (29 male, 7 
female) (clinic referred).  
Age: 9-14 years. 
 
 
QbTest improved after MPH and Dex but not after 
placebo. Activity measure had largest effect size.  
Convergent validity for rating scales and the QbTest 
were found on a group level, but not on an individual 
level. 
 
Ramtvedt et 
al. (2013)[76] 
Cross-over RCT 
(MPH/Dex/ 
Placebo) 
QbTest ADHD-questionnaire 36 children (29 male, 7 
female) with ADHD 
(clinic referred). 
Age: 9-14 years. 
 
Significant treatment effects for stimulant drugs on both 
QbTest and rating scale. Including both stimulants 
favourable responses increased from 72% to 92%. 
 
Reh et al. 
(2013) [70] 
Cross-sectional 
 
QbTest 
 
Clinical Assessment 
(DSM-IV-TR); CPRS; 
CTRS; KITAP; PACS;  
WISC-IV 
Sample 1: 828 children  
(588 males, 240 females) 
(clinic referred). 
Age: 6-12 years.  
Sample 2: 102 children  
(79 males, 23 females) 
diagnosed with ADHD 
Age: 6-12 years 
 
In children referred for an ADHD diagnosis a three-
factor model (attention, impulsivity and activity) 
explained 76% of the total variance in QbTest data; the 
activity parameter explained the largest amount of 
variance.  
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Reference Design Activity test Other assessments Sample Main relevant outcomes 
 
Teicher et al. 
(1996) [51] 
Cross-sectional  M-MAT  CBCL; Clinical 
Assessment (DSM IV); 
CPRS; CTRS; IOWA  
K-SADS-E;  
29 children (all males):  
18 with ADHD (clinic 
referred); 11 control 
(community sample). 
Age: 6-14 years.  
 
Boys with ADHD moved their head 2.3 times more often 
than normal children, 3.4 times as far, and had a more 
linear and less complex movement pattern. Boys with 
ADHD had slower responses and greater variability on 
CPT relative to controls.  
Wehmeier et 
al. (2011) [74] 
Double-blind 
Placebo-
controlled,  
RCT 
(ATX/Placebo) 
 
QbTest ADHD-RS-IV-P; CGI-
S; Clinical Interview 
(DSM-IV-TR); DCHD;  
WREMB-R-Inv 
 
128 children (99 male, 29 
female) with ADHD 
(clinic referred).Age: 6-12 
years. 
 
 
Both the ATX and placebo groups showed a circadian 
pattern of neuropsychological outcomes. ATX was 
shown to have a positive effect on activity ratings. 
 
Wehmeier et 
al. (2012)[72] 
Double-blind 
Placebo-
controlled,  
RCT 
(ATX/Placebo) 
 
QbTest ADHD-RS; CGI-S;  
WREMB 
 
135 children (105 male, 30 
female) with ADHD 
(clinic referred). Age: 6-12 
years. 
 
Similar to the findings of the previous study actigraphy 
was sensitive to ATX. 
  
ADHD-RS(IV-P) ADHD Rating Scale (IV-Parent Version), ATX Atomexetin, CBCL Child Behavior Checklist, CGI-S Clinical Global Impressions Scale – Severity, DCHD 
Diagnostic Checklist for Hyperkinetic Disorders, Dex Dextroamphetamine, FBB-HKS The German Behavioural rating scale for ADHD; Fremdbeurteilungsbogen für 
Hyperkinetische Störungen (T= Teacher rated) section of DSIYPS (Diagnostik-System für Psychische Störungen im Kindes- und Jugendalter), K-DIPS German semi-
structured interview, MPH-IR/MPH-Ret Methylphenidate immediate release/Retard, TRS Teacher Rating Scale, WISC-III Wechsler Intelligence Scale for Children, 3rd 
edition, WREMB(-R-Inv) Weekly Ratings of Morning and Evening Behavior (Revised-Investigator Rated Scale) 
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FIGURE 1: Flow diagram illustrating study selection process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Potentially relevant studies identified 
and screened for retrieval 
N = 1421 (after duplicates removed) 
Papers excluded on title and abstract = 1300 
Not: 
i) Humans = 104 
ii) ADHD = 769 
iii) Children (up to 18 years) = 96 
iv) Published in peer review journal = 89 
v) A commercially available CPT = 13 
vi) Clinical utility = 215 
vii) English = 14 
Full papers retrieved from search 
N = 121 
Additional papers identified via hand 
searching 
N = 7 
 
Publications excluded after reading paper = 68 
Not: 
i) Humans = 0 
ii) ADHD = 2 
iii) Children (up to 18 years) = 3 
iv) Published in peer review journal = 3 
v) A commercially available CPT = 1 
vi) Clinical utility = 58 
vii) English = 1 
 
Studies included in review  
N = 60 
Figure
TABLE 1: Search strategies to identify studies for inclusion 
 
Searches: 
1. ADHD OR attention deficit hyperactivity disorder OR attention OR hyper$ OR ADD$ OR attention deficit 
disorder  
2. Continuous Performance Test OR Continuous Performance Task OR Auditory Continuous Performance Test 
OR ACPT OR CANTAB OR Conner$ CPT OR CCPT OR Gordon$ Diagnostic System OR GDS OR Integrated 
Visual and Auditory test OR IVA OR QbTest OR Seidel Continuous Attention Test OR SCAT OR Test of 
Variables of Attention OR TOVA 
3. diagnosing OR assessing OR medication management OR titration OR treatment monitoring OR response 
OR drug OR medication  
4. motor activity OR measure$ OR quantifying 
$ indicates a wildcard character 
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